Retatrutide answers depend on what the studies checked.
Retatrutide liver findings concern fat, rather than healed scars
Testing continues on retatrutide, a possible future treatment. These answers explain the findings and the choices those findings can't settle. The liver study had just 98 volunteers. With 12 milligrams, liver fat fell −82.4% after 24 weeks. That is the change in fat already present. Eighty-six percent reached normal liver fat, below 5% [5]. The fall reached −86.0% at 48 weeks.
Less fat doesn't prove your liver scars would heal.
Retatrutide may reduce eating and increase fuel use
Retatrutide copies three hormones, which carry messages around your body. GLP-1 curbs hunger and makes meals pass through your stomach more slowly. GIP adds to insulin release when a meal is eaten. Glucagon increases calorie use and helps break down liver fat. Separate early studies reported larger weight and sugar falls than with drugs copying fewer hormones. Phase 3, larger tests before an approval request, was still running [6]. Those separate studies can't establish the best drug for you.
Retatrutide weight losses were averages across study volunteers
Retatrutide attaches where cells receive GLP-1, GIP, and glucagon messages. GLP-1 reduces hunger; GIP helps release insulin; glucagon helps burn fuel. Phase 2 means early tests of whether treatment helps people. At 12 milligrams, weight fell −24.2% on average over 48 weeks. With placebo, meaning a shot that lacked retatrutide, weight fell −2.1% [1]. Those are shares of starting weight lost. Your weight won't necessarily change by the group's average.
Retatrutide powder has no checked home mixing instructions
No approved retatrutide directions cover mixing research bottles. You can't count on the stated drug being inside or free of germs and bacterial poisons. Study staff use prepared medicine under medical checks; outside bottles haven't been shown to replace that medicine safely. Sellers received FDA warnings in more than 50 letters during 2025. Mixing powder doesn't supply the missing tests of contents and cleanliness. Your bottle remains unapproved after mixing.
Retatrutide had not entered the FDA approval review
In mid-2026, retatrutide still lacked approval from the FDA and other drug regulators. Eli Lilly's Phase 3 tests, larger checks of benefit and harm, were running under TRIUMPH. Phase 3 findings must be finished and reviewed before an approval request. The company hadn't submitted that request; testing itself had already begun. Tirzepatide and semaglutide have their own approvals. Those decisions don't establish whether retatrutide will suit your health.
Retatrutide release guesses cannot give you a treatment date
You had no confirmed release date as of mid-2026. Phase 3, larger tests before an approval request, was active. Analysts used Phase 3 timing to guess that a request might come in 2026–2027. Eli Lilly hadn't confirmed that timing. Phase 3 findings would still need review before approval could be decided. A guessed filing date isn't a date for receiving treatment. Your plans can't rest on an unconfirmed release.
Retatrutide injections in studies came with medical supervision
The published reports describe shots each week in fat just under skin. Staff gave the shots, or taught volunteers under medical supervision. The reports don't establish another tested way to receive the drug. You can't turn that study schedule into a plan for yourself. Retatrutide lacks approval, and volunteers had medical checks alongside the shots. Knowing where a shot went doesn't answer the risks of your own health or an outside bottle.
Retatrutide changes began early but continued over months
Phase 2, early tests of benefit, found weight beginning to fall early. Loss was fastest during the first 20 to 24 weeks. At 12 milligrams, weight fell −24.2% on average by 48 weeks [1]. Liver fat fell −82.4% by week 24 [5]. The roughly 6-day fall is the time drug levels take to drop by half. After roughly 4 to 5 weekly shots, the amount of drug in blood followed a steady rise and fall [4]. These aren't deadlines for your results.
Retatrutide and tirzepatide figures do not establish a winner
The published studies didn't give both drugs to matching groups under the same conditions. A review covered 26 studies and 15,491 adults without diabetes. Retatrutide at 12 milligrams showed 22.1% weight loss over 48 weeks. Tirzepatide at 15 milligrams showed 17.8% over 72 weeks [9]. Different people and study lengths prevent a fair choice for you. TRIUMPH is studying the drugs directly, which should provide a sounder comparison.
Retatrutide amounts were increased with staff watching for harm
Phase 2, early tests of benefit, used 1 milligram, 4 milligrams, 8 milligrams, and 12 milligrams in the weight and liver studies [1][5]. Volunteers received weekly shots. In type 2 diabetes, weekly amounts rose from 0.5 milligrams to 12 milligrams [2]. Staff watched people's health during those changes. You can't read those figures as a prescription. The studies don't establish safety at those amounts without medical checks.
Water cannot establish the safety of retatrutide powder
No approved water-mixing method exists for retatrutide. Medical studies use prepared drug under staff's care. People mixing research-labeled powder at home don't have those same checks. Sellers describe general ways to mix powders, but no proven rule establishes safety for these bottles. Officials have warned sellers about such products. You can't tell whether a bottle contains the stated drug, or whether the contents are clean, from instructions about adding water.
A switch to retatrutide has no tested plan
Researchers haven't tested switching between tirzepatide and retatrutide. Tirzepatide has approved uses, while retatrutide remains unapproved. Your health and the available studies would need review by your doctor. A review found weight-related gains with both drugs, including tests linked to liver fat [12]. That doesn't establish how to change the medicines safely. Improvement in separate studies can't answer what happens during a switch in your own treatment.
GLP-3 is a mistaken name for retatrutide
“GLP-3” doesn't name a hormone that retatrutide copies. There is no GLP-3 attachment place for this drug on cells. Retatrutide copies GLP-1, GIP, and glucagon, hormones involved in appetite, insulin release, and burning fuel. People may confuse three hormone effects with a new hormone called “GLP-3,” but GIP/GLP-1/glucagon names the actual effects [3], rather than adding a new hormone or another action to the drug. The nickname alone tells you nothing about safety.
Retatrutide outside a study lacks assured contents
You can receive checked retatrutide through enrollment in a medical study. There's no approved medicine for ordinary prescription use. Outside sellers offer research-labeled bottles, with no assurance about the drug or cleanliness. During 2025, more than 50 FDA warning letters cited retatrutide sellers for breaches of drug law. A bottle being offered doesn't mean the bottle is approved for treatment or has the study drug's checks.
Retatrutide is being tested for weight and organ health
Researchers are testing retatrutide for obesity, type 2 diabetes, liver fat, heart risk, and lasting kidney illness. None has an approved use yet. In Phase 2, early tests of benefit, adults with obesity lost −24.2% weight on average over 48 weeks. The sugar blood test improved in type 2 diabetes. Liver fat fell −82.4% in the liver study [1][2][5]. Those early findings can't establish all the proposed uses for you.
Retatrutide attaches where cells receive three hormone messages
Cells have places that receive hormone messages and start a response. Retatrutide attaches where GLP-1, GIP, and glucagon messages arrive. Those hormones affect hunger, insulin release, and fuel use. Tests in cells confirmed attachment at all three places [3]. The GIP response was strongest. Approved drugs may copy GLP-1 alone or GLP-1/GIP together. Retatrutide adds glucagon. Strong cell responses don't tell you your weight loss or lasting safety.
Retatrutide sellers can breach the law despite research labels
No approved retatrutide medicine exists to prescribe. US sellers can breach federal drug law by offering research bottles, as FDA warning letters in 2025 showed. Rules for possessing research material differ by area and remain unclear. You can't infer legal medical use from a sales listing.
For competitive sport, WADA is the World Anti-Doping Agency, which sets rules on banned drugs. GLP-1/GIP/glucagon names hormone effects involved in hunger, insulin, and fuel use. Those drugs aren't specifically named on the list described here, but rules for test drugs can change. A sports rule doesn't establish medical safety for you.
Retatrutide weekly study shots reflected slow clearing
Study volunteers received shots beneath the skin [1][2][4][5]. The roughly 6-day fall describes how long blood levels take to halve [4]. That slow fall helped maintain effects between weekly shots. Phase 1 checked early safety; Phase 2 checked benefit; Phase 3 tested larger groups. Published reports don't establish other intervals. You can't use a study's timing as directions for yourself without its medical checks.
Retatrutide can remain after the shots stop
Early human testing found about half the drug in blood after 6 days [4]. An attached fat helps retatrutide stick to the blood protein called albumin. The protein slowly releases the drug. That roughly 6-day fall helps explain weekly study shots. After about 4 to 5 doses, drug levels rise and fall within a steady range. Clearing retatrutide takes weeks after stopping. Your last shot doesn't immediately end the effects.
Retatrutide bottles have no approved safe keeping time
Retatrutide has no approved storage directions for your bottle. Study staff keep the drug cold under rules that aren't public. For other drugs made from short protein chains, powders are often kept at −20°C or colder, well below freezing. Mixed liquids are often kept at 2 to 8°C, refrigerator cold. The C marks degrees on the celsius scale. Neither temperature is tested guidance for retatrutide, and no safe keeping time is established for your bottle.
Retatrutide and semaglutide are different medicines
Semaglutide copies GLP-1, a hormone involved in blood sugar and hunger control. Retatrutide copies GLP-1, GIP, and glucagon together. Those added effects involve insulin release and fuel use. Semaglutide has drug approval; retatrutide is still being tested. Although both belong to the broad family of weight and sugar drugs, you can't simply exchange one for the other. The findings and safety questions for each medicine need their own review.
Retatrutide and semaglutide need a fair direct test
Moiz and colleagues reviewed separate studies rather than a direct drug test. The review covered 26 studies and 15,491 adults without diabetes. At 12 milligrams, retatrutide showed 22.1% weight loss at 48 weeks. Semaglutide at 2.4 milligrams showed 13.9% at 68 weeks [9]. Differences in people and study length prevented one fair average comparing the drugs. You need matching groups and conditions to establish which works better. Planned TRIUMPH work aims to provide that comparison.